Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

Basit Öğe Kaydı
dc.authorid0000-0002-6833-5646en_US
dc.authoridQ2en_US
dc.authorscopusid6507971898en_US
dc.authorwosidC-7080-2019en_US
dc.contributor.authorSoysal, Ahmet
dc.contributor.authorGönüllü, Erdem
dc.contributor.authorKarabayır, Nalan
dc.contributor.authorAlan, Servet
dc.contributor.authorAtıcı, Serkan
dc.contributor.authorYıldız, İsmail
dc.contributor.authorEngin, Havva
dc.contributor.authorÇivilibal, Mahmut
dc.contributor.authorKaraböcüoğlu, Metin
dc.date.accessioned2021-12-21T12:31:46Z
dc.date.available2021-12-21T12:31:46Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractThe effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15-136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202-10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8-15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals.en_US
dc.identifier.citationSoysal, A., Gönüllü, E., Karabayır, N., Alan, S., Atıcı, S., Yıldız, İ., Engin, H., Çivilibal, M., & Karaböcüoğlu, M. (2021). Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers. Human Vaccines & Immunotherapeutics. pp. 1-5. https://doi.org/10.1080/21645515.2021.1953344en_US
dc.identifier.doi10.1080/21645515.2021.1953344en_US
dc.identifier.endpage3880en_US
dc.identifier.issue11en_US
dc.identifier.pmidPMID: 34324409en_US
dc.identifier.scopus2-s2.0-85111796073en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage3876en_US
dc.identifier.urihttps://doi.org/10.1080/21645515.2021.1953344
dc.identifier.urihttps://hdl.handle.net/20.500.13055/100
dc.identifier.volume17en_US
dc.identifier.wosWOS:000679215500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expandeden_US
dc.institutionauthorGönüllü, Erdem
dc.language.isoenen_US
dc.publisherTaylor and Francisen_US
dc.relation.ispartofHuman Vaccines and Immunotherapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSARS-CoV-2 Inactivated Virus Vaccineen_US
dc.subjectCoronaVacen_US
dc.subjectHealth Care Workersen_US
dc.subjectVaccine Antibody Responseen_US
dc.subjectVaccine Adverse Effectsen_US
dc.subjectTurkeyen_US
dc.titleComparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workersen_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Comparison of immunogenicity and reactogenicity of inactivated SARS CoV 2 vaccine CoronaVac in previously SARS CoV 2 infected and uninfected healthh.pdf
Boyut:
336.22 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu